恩替卡韦治疗慢性乙型肝炎患者对血清及单个核细胞内病毒量的影响

目的 观察恩替卡韦治疗对慢性乙型肝炎患者血清及单个核细胞（PBMC）内HBV-DNA水平的影响.方法 选取住院慢性乙型肝炎患者110例,随机分为两组,观察组给予恩替卡韦片0.5mg/d治疗,对照组予拉米夫定100mg/d治疗.检测治疗后12、24及48周血清及单个核细胞内HBV-DNA水平.结果 治疗48周后,观察组患者血清HBV-DNA阴转率为82.7%,对照组为51.9%（P〈0.05）;PBMC内HBV-DNA阴转率,观察组为57.7%,对照组为31.5%,两组间差异有统计学意义（P〈0.05）.结论 对于血清及单个核细胞内的乙型肝炎病毒,恩替卡韦均具有较强的抑制病毒复制的能力,其疗效优于拉米夫定.

Objective To study the dynamic changes of hepatits B virus （HBV） DNA in serum and peripheral blood mononuclearcells （PBMCs） of patients after entecavir therapy. Methods A total of 110 patients with chronic HBV infection were randomly divided into treatment group and control group averagely. The patients in treatment group were given by entecavir 0.5mg/d while those in control group were treated with lamivudine 100mg/d. HBV -DNA was detected both in serum and in PBMCs during and after lamivudine treatment. Results In the treatment group, HBV - DNA became negative in serum and in PBMC, is 43 （ 82. 7% ） and 30 （ 57.7% ） cases respectively during the 48 weeks of entecavir treatment. In the control group, the negative was 28 （51.9%） and 17 （31.5%） respectively （P 〈 0. 05 ）. Conclusion Entecavir has remarkable inhibitory effects on HBV replication both in serum and in PBMCs and is stronger than that of Lamivudine.